Disc Medicine enters into $100M at-the-market equity facility with SVB Securities

On January 25, 2023, Disc Medicine, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with SVB Securities LLC (“SVB Securities”) pursuant to which the Company may, from time to time in its sole discretion, issue and sell through SVB Securities, acting as sales agent, shares of the Company’s common stock, par value $0.0001 per share (the “Placement Shares”). The issuance and sale, if any, of Placement Shares with an aggregate offering price of up to $100.0 million by the Company under the Agreement will be made pursuant to a prospectus supplement to the Company’s registration statement on Form S-3 (File No. 333-269272), originally filed with the Securities and Exchange Commission (the “SEC”) on January 18, 2023, which became effective on January 24, 2023.